relapsed — TargetMol Chemicals

Cat No.	Product Name	Synonyms	Targets
T12367	Parsaclisib	INCB050465	PI3K
	Parsaclisib (INCB050465) is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP)		PI3K
T28297	Parsaclisib hydrochloride	Parsaclisib HCl,INCB-50465,INCB 050465,INCB-050465,INCB050465 HCl,INCB 50465,INCB50465 HCl	PI3K
	Parsaclisib hydrochloride (INCB050465 HCl) is a selectve PI3Kδ inhibitor with antitumor activity. Parsaclisib demonstrates potent activity with IC50 values ranging from 0.2 to 2 nM.		PI3K
T76927	Bersanlimab	BI-505	Integrin
	Bersanlimab (BI-505) is a fully human monoclonal antibody targeting Intercellular Adhesion Molecule-1 (ICAM-1).Bersanlimab has anticancer properties and can be used to study relapsed/refractory multiple myeloma.		Integrin
T71973	Gilteritinib hemifumarate	ASP2215 hemifumarate	FLT , TAM Receptor
	Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of relapsed or refractory FLT3 mutant AML.		FLT , TAM Receptor
T3078	SGI-1776	SGI-1776 free base,Pim-Kinase Inhibitor IX	Apoptosis , FLT , Pim , Autophagy
	SGI-1776 (Pim-Kinase Inhibitor IX) has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.		Apoptosis , FLT , Pim , Autophagy
T76718	Brentuximab		TNF
	Brentuximab is a chimeric antibody targeting CD30 and is a naked antibody to Brentuximab vedotin.Brentuximab has antitumor activity and may be used to study relapsed or refractory Hodgkin's lymphoma.		TNF
T77750	Rosmantuzumab	OMP-131R10	Others
	Rosmantuzumab (OMP-131R10) is a humanized monoclonal antibody against R-spondin 3 (RSPO3). Rosmantuzumab has potential antitumor activity and can be used to study advanced relapsed refractory solid tumors.		Others
T76685	Glofitamab	RO7082859,RG 6026,CD20-TCB	Others
	Glofitamab (RO7082859) is a novel bivalent antibody directed against CD20-binding T cells.Glofitamab promotes T cell proliferation and activation and tumor cell killing by binding to CD20 on malignant cells.Glofitamab ca...		Others
T77909	Mirzotamab
	Mirzotamab, an IgG1κ antibody, targets CD276/B7-H3 and conjugates with Clezutoclax, a BCL-2 inhibitor, to create Mirzotamab clezutoclax. This antibody-drug conjugate (ADC), identified as ABBV-155, is currently under inve...
T76692	Mosunetuzumab	BTCT-4465A	Others
	Mosunetuzumab (BCT-4465A) is a humanized antibody based on immunoglobulin G1 that targets CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used to stu...		Others
T9969	EZM0414		Histone Methyltransferase
	EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 with IC50 of 18 nM in SETD2 biochemical assay and IC50 of 34 nM in a cellular assay. EZM0414 can be used for the research of relapsed or refractory m...		Histone Methyltransferase
T31450	Diethylstilbestrol dipropionate
	Diethylstilbestrol dipropionate can be used in estrogen therapy of relapsed prostate cancer.
T13279	Valemetostat tosylate	DS-3201 tosylate	Histone Methyltransferase
	Valemetostat tosylate is a dual inhibitor of EZH1/2 and used in the research of relapsed/refractory peripheral T-cell lymphoma.		Histone Methyltransferase
T80863	Visugromab	CTL-002	PD-1/PD-L1
	Visugromab, a GDF-15 neutralizing IgG4 monoclonal antibody (mAb), demonstrates potent efficacy in treating PD-1/PD-L1 relapsed/refractory metastatic solid tumors [1].		PD-1/PD-L1
T70759	CUDC-907 mesylate
	CUDC-907 mesylate is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multi...
T82927	Azintuxizumab
	Azintuxizumab, an IgG4 bispecific antibody, specifically targets the B-cell maturation antigen (BCMA) and shows promise for the investigation of relapsed/refractory multiple myeloma (RRMM) [1].
T79377	NWP-0476
	NWP-0476 is a modified BCL-2/BCL-xL inhibitor with enhanced specificity for BCL-xL, suitable for research on relapsed T-acute lymphoblastic leukemia (T-ALL) [1].
T62524	Panobinostat lactate
	Panobinostat lactate is a potent, orally active, non-selective HDAC inhibitor with antitumor effects. Panobinostat lactate can be used to study refractory or relapsed multiple myeloma.
T80613	Linvoseltamab	REGN5458
	Linvoseltamab, a bispecific antibody, targets both BCMA (TNFRSF17) and CD3 epsilon, demonstrating a favorable safety profile and promising efficacy in relapsed/refractory multiple myeloma (RRMM) [1][2].
T77084	Mezagitamab
	Mezagitamab (TAK-079), an IgG1λ anti-CD38 monoclonal antibody, functions by depleting tumor cells that express CD38 through both antibody and complement-dependent cytotoxicity. It shows potential for use in the treatment...